Stroke continues to be the most serious and debilitating neurological disorder in the United
States. With a new event every 40 seconds and a victim every 4 minutes, it is the fifth leading …

To demonstrate thrombolytic efficacy of a tissue plasminogen activator (tPA)-loaded
echogenic liposome (TELIP) formulation in a rabbit thrombotic stroke model (the most …

This chapter describes the recent developments and breakthroughs in ultrasound-
responsive nanomedicine. Clinical therapeutic ultrasound applications primarily utilize high …

Ischemic stroke affects nearly 700,000 patients in the United States each year and is the fifth
most common cause of death. In less than 6% of ischemic stroke patients, lysis of the …

溶栓剂已广泛用于脑卒中的治疗, 其延长治疗时间窗的作用也引起了关注, 由于药非靶向治疗,
因此在治疗中常会出现一些副作用, 如出现系统性纤维蛋白原溶解和出血等 …

Systemic delivery of therapeutic agents for treating a wide range of diseases can be
challenging, where treatment effectiveness is determined by the total dose of drug delivered …

Stroke is responsible for 11% of all deaths worldwide, the majority of which are caused by
ischemic strokes, thus making the need to find safe and effective therapies urgent. Today …

Objective: This study aimed to prepare the arginine-glycine-aspartic acid (RGDS)-urokinase-
carrying targeting ultrasound contrast agent using the avidin-biotin system (BAS) and to …

Thrombosis is the leading cause of death and disability. Clots (ie thrombi) that obstruct blood
flow from delivering oxygen and nutrients to tissues require rapid removal. The main …

Stroke is one of the major causes of death worldwide, and the thrombolytic drug alteplase
(tissue plasminogen activator or tPA) is the only treatment available for acute ischemic …